Triphosphate

Triphosphate

SCHEMBL595229

O=P(O)(O)OP(=O)(O)OP(=O)(O)O.c1ncc2[nH]cnc2n1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.38
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NTRK1 P04629 1/20 0.31
FDPS P14324 1/20 0.31
METAP2 P50579 1/20 0.30
METAP1 P53582 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL637333 0.94 ALDH1A1 (0.35) P2RX3ALDH1A1KDM4ERXFP1NTRK1
Triphosphate SCHEMBL7453135 0.92 P2RX3 (0.35) P2RX3
Triphosphate SCHEMBL9104232 0.90 P2RX3 (0.36) P2RX3
Purine SCHEMBL27554272 0.87 ALDH1A1 (0.39) ALDH1A1KDM4ERXFP1NTRK1FDPS
Purine SCHEMBL5989434 0.87 ALDH1A1 (0.39) ALDH1A1KDM4ERXFP1NTRK1FDPS
Purine SCHEMBL595231 0.87 ALDH1A1 (0.39) ALDH1A1KDM4ERXFP1NTRK1FDPS
Purine SCHEMBL2676962 0.84 ALDH1A1 (0.41) ALDH1A1KDM4ERXFP1NTRK1FDPS
Purine SCHEMBL28271 0.80 ALDH1A1 (0.39) ALDH1A1KDM4ERXFP1METAP2METAP1
Purine SCHEMBL28164598 0.80 ALDH1A1 (0.44) ALDH1A1KDM4ERXFP1METAP2METAP1
Purine SCHEMBL3158 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2812441-A1 NUCLEIC ACID LIGATION METHOD Wisconsin Alumni Research Foundation (US) 2014-12-17 EP claimed
WO-2013119690-A1 NUCLEIC ACID LIGATION METHOD WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-08-15 WO claimed
US-20130203635-A1 NUCLEIC ACID LIGATION METHOD WISCONSIN ALUMNI RESEARCH FOUNDATION 2013-08-08 US claimed
CN-1735693-A Method for in vitro screening of 2' -substituted nucleic acids ARCHEMIX CORP (US) 2006-02-15 CN claimed
US-20230346827-A1 TREATMENT OF CORONAVIRUS INFECTIONS TX MEDIC AB (SE) 2023-11-02 US disclosed
EP-4135719-A1 TREATMENT OF CORONAVIRUS INFECTIONS TX Medic AB (SE) 2023-02-22 EP disclosed
CN-108472371-B EGFR antibody-drug conjugate and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-05-24 CN disclosed
WO-2021211043-A1 TREATMENT OF CORONAVIRUS INFECTIONS TX MEDIC AB (SE) 2021-10-21 WO disclosed
US-10894946-B2 Multiloop engineered heart muscle tissue TISSUE SYSTEMS HOLDING GMBH (DE) 2021-01-19 US disclosed
US-20200140820-A1 MULTILOOP ENGINEERED HEART MUSCLE TISSUE UNIVERSITATSKLINIKUM HAMBURG-EPPENDORF (DE) 2020-05-07 US disclosed
US-10494605-B2 Multiloop engineered heart muscle tissue TISSUE SYSTEMS HOLDING GMBH (DE) 2019-12-03 US disclosed
CN-107653330-A A kind of multiple PCR reagent kit and its discrimination method of quick discriminating On Planthopperss 中国水稻研究所 2018-02-02 CN disclosed
WO-1998045313-A1 NOVEL UNCOUPLING PROTEIN AND METHODS OF USE AMYLIN PHARMACEUTICALS, INC. (US) 1998-10-15 WO disclosed
WO-1998042869-A1 MAMMALIAN DNA PRIMASE SCREENS AND ACTIVITY MODULATING AGENTS GERON CORPORATION (US) 1998-10-01 WO disclosed
US-5801184-A Carbon monoxide dependent guanylyl cyclase modifiers and methods of use SPECTRUM PHARMACEUTICALS, INC. 1998-09-01 US disclosed
CN-1154065-A Carbon monoxide dependent guanylyl cyclase effectors GLASKY ALVIN J (US) 1997-07-09 CN disclosed
EP-0772440-A1 CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS GLASKY, Alvin J. (US) 1997-05-14 EP disclosed
WO-1996006621-A1 METAL COMPLEX CONTAINING OLIGONUCLEOSIDE CLEAVAGE COMPOUNDS AND THERAPIES GENTA INCORPORATED (US) 1996-03-07 WO disclosed
WO-1996003125-A1 CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS GLASKY ALVIN J (US) 1996-02-08 WO disclosed
US-5447939-A Purine derivatives used for long term modification of neural activity in mammals, for treatment of mammalian neurological diseases, and for inducing long term changes in membrane potential of mammalian neuron SPECTRUM PHARMACEUTICALS, INC. 1995-09-05 US disclosed